New triple-drug attack targets hard-to-treat lymphoma
NCT ID NCT07548255
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This early-stage study tests whether combining three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) can shrink or eliminate mantle cell lymphoma in people with aggressive forms of the disease. About 28 newly diagnosed patients with high-risk features will receive the combination as their first treatment. The main goal is to see how many achieve a complete response after six cycles, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE-TO-HIGH-RISK MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.